Rezvilutamide
- Generic Name
- Rezvilutamide
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于治疗高瘤负荷的转移性激素敏感性前列腺癌（mHSPC）患者。
- Associated Conditions
- -
- Associated Therapies
- -
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 40
- Registration Number
- NCT06387056
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06348264
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Peking University School and Hospital of Stomatology, Beijing, Beijing, China
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 102
- Registration Number
- NCT06305832
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
🇨🇳The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jianbin Bi
- Target Recruit Count
- 160
- Registration Number
- NCT06134271
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 200
- Registration Number
- NCT05983783
- Locations
- 🇨🇳
Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2023-03-06
- Target Recruit Count
- 96
- Registration Number
- NCT05753566
- Locations
- 🇨🇳
JiangSu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2022-08-16
- Target Recruit Count
- 900
- Registration Number
- NCT05406999
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.